Sign in
CompletedPhase 2

Phase 2 Study of pH Gastrilex™ (Enteric-Coated Amorphous Calcium Carbonate Capsules) in Moderate-to-Severe Crohn's Disease

Key facts

Who runs it
Soroka University Medical Center
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
23 people enrolled
Started
11 Jun 2023
Ended
19 Feb 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PH Gastrilex
  • Placebo Comparator
Record updated
10 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Signed informed consent form
  • Men and women, age 18 years and older
  • Moderate to severe CD patients. Moderately active disease will be defined by a CDAI score between 220 to 450, and severe disease for CDAI score greater than 450

Who cannot take part

  • Participation in a clinical trial with, or use of, any investigational agent within 30 days or 5 half-lives, whichever is longer, before starting treatment in the trial
  • Subject who is taking oral corticosteroids:; Budesonide >9mg/day; Prednisone or equivalent> 20 mg/day; Or has not been on a current course for>14 days prior to colonoscopy
  • Subjects who received an approved biological agent less than 16 weeks prior screening
  • Subjects whose treatment dose has not been stable for at least 14 days before Baseline, or who discontinued treatment within 14 days before Baseline
  • Other significant medical conditions that may require intervention during the trial
  • Women patients who are pregnant or breastfeeding. Women patients must have a negative urine or serum test at screening and a negative urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of human chorionic gonadotropin [hCG] at baseline, within 24 hours prior to the start of any investigational agent). Male patients with female sexual partners who are pregnant
  • Hypoparathyroidism
  • Subjects with consistent hypercalcemia or hypercalciuria

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This Phase 2 study aims to evaluate the safety, tolerability, and efficacy of pH Gastrilex™, an enteric-coated capsule formulation containing amorphous calcium carbonate (ACC), in adults with moderate-to-severe Crohn's disease.

The 2 groups in the trial

  • PH Gastrilex™Treatment being tested

    PH Gastrilex™ (Amorphous Calcium Carbonate)

  • Placebo groupPlacebo, for comparison

    Placebo Followed by PH Gastrilex™ (Amorphous Calcium Carbonate)

    Treatment: Placebo Comparator

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Randomized, Parallel, Double Blind, Placebo-Controlled Study, Followed by an Open Label Extension, to Assess the Safety, Tolerability, and Efficacy of pH Gastrilex™ (Enteric-Coated Capsules Containing Amorphous Calcium Carbonate) Administered Concomitantly With Best Available Treatment (BAT) in the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
Record updated
10 November 2026